HLB Pep Co., Ltd. Logo

HLB Pep Co., Ltd.

Biopharmaceutical firm specializing in peptide-based drug R&D and manufacturing.

196300 | KO

Overview

Corporate Details

ISIN(s):
KR7196300008
LEI:
Country:
South Korea
Address:
광주광역시 북구 첨단과기로 333 광주테크노파크 시험생산동 206호 , 광주광역시

Description

HLB Pep Co., Ltd. is a biopharmaceutical company specializing in the research, development, and production of peptide-based biomaterials and new drugs. The company's core activities include the manufacturing of peptide Active Pharmaceutical Ingredients (APIs) in a GMP-certified facility. It offers a range of products and services, including generic peptides, custom peptide synthesis for research and development, and a catalog of approximately 1,000 research peptides such as hormones and neuropeptides. HLB Pep focuses on discovering new drug candidates and aims to commercialize them through technology transfer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-06 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 72.6 KB
2025-02-07 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 68.9 KB
2025-02-04 00:00
주권매매거래정지 (관리종목지정우려)
Korean 5.0 KB
2025-02-04 00:00
내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생
Korean 17.2 KB
2025-01-15 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 80.0 KB
2024-12-30 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 41.6 KB
2024-12-26 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 43.2 KB
2024-12-20 00:00
주요사항보고서(유상증자결정)
Korean 39.5 KB
2024-12-19 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 21.4 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 638.9 KB
2024-10-21 00:00
투자판단관련주요경영사항 (가니렐릭스 원료의약품 미국식품의약국(FDA) 품목허가 신청)
Korean 7.8 KB
2024-09-05 00:00
소송등의판결ㆍ결정
Korean 5.0 KB
2024-09-04 00:00
소송등의제기ㆍ신청(경영권분쟁소송) (주주총회소집허가)
Korean 6.4 KB
2024-08-14 00:00
반기보고서 (2024.06)
Korean 783.2 KB

Automate Your Workflow. Get a real-time feed of all HLB Pep Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Pep Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Pep Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.